Trial Profile
A multicenter retrospective study to evaluate the safety and efficacy of bendamustine–rituximab (BR) in previously untreated patients with chronic lymphocytic leukaemia (CLL).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 May 2016
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 05 May 2016 New trial record
- 26 Apr 2016 Results published in the European Journal of Cancer